Skip to content

Implementation of Family Involvement for Persons With Psychotic Disorders.

Implementation of Guidelines on Family Involvement for Persons With Psychotic Disorders in Community Mental Health Centres. A Cluster Randomised Controlled Trial.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03869177
Acronym
IFIP
Enrollment
460
Registered
2019-03-11
Start date
2019-03-21
Completion date
2022-05-30
Last updated
2023-01-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psychotic Disorders

Keywords

Family psychoeducation, Schizophrenia, Implementation science, Mental health care services, Clinical ethics, Family involvement, Family intervention

Brief summary

This study will develop and evaluate a complex intervention to implement guidelines on family involvement for patients with psychotic disorders (F20-29 in International Classification of Diseases ICD-10) in community mental health centres, by using a cluster randomised design. Fifteen Norwegian outpatient units participate in the study, and each of them constitutes a single cluster, except for two collaborating clinics who are considered one cluster. Of the fourteen clusters, half will receive implementation support and training immediately, whereas the other half will receive it one and a half year later. The study will assess both service level outcomes, by measuring fidelity scores, and selected outcomes for patients and relatives, by collecting questionnaires and data from central health registers and patient records. In addition, qualitative interviews will be performed with patients, relatives and health care personnel. The study will also include a cost-effectiveness analysis and a political economy analysis.

Detailed description

Background: Family involvement during severe mental illness, such as psychotic disorders, is both important and challenging. Evidence suggest that family interventions for persons with psychotic disorders are associated with positive outcomes for both relatives and patients, and economic analyses of such interventions consistently report net saving. There are also important moral imperatives to involve those providing unpaid and informal care. Yet research has shown that relatives of patients with severe mental illness experience little involvement, and that the implementation of family interventions is patchy. The Norwegian national guidelines on family involvement in the public health- and care services and the national guidelines on psychotic disorders, both give recommendations on family involvement. However, there is little knowledge about how to achieve their implementation, and whether a high degree of implementation will be associated with improvements in selected outcomes for patients and relatives. Setting: Fifteen outpatient units from community mental health centres in the South-Eastern Norway Regional Health Authority. Research questions: 1. What is the current level of implementation of the selected recommendations in the national guidelines on family involvement for persons with psychotic disorders in participating clinical units? 2. What are important barriers to and facilitators for implementing the national guidelines among the stakeholders at the clinical, organisational, and policy level? 3. What are important moral dilemmas and conflicting interests related to family involvement, and how can these be resolved? 4. Is implementation of the selected recommendations increased by a comprehensive implementation support program, compared with no such support? 5. Is a higher level of implementation of the selected recommendations associated with improvements in selected outcomes for patients and relatives? 6. Is implementation of family involvement during primary psychotic disorders a cost-effective intervention? Hypotheses: 1. The current implementation of the selected recommendations in the national guidelines on family involvement for persons with psychotic disorders is low. 2. There are important barriers to and facilitators for implementing the national guidelines among the stakeholders, at the clinical, organisational and policy level. 3. There are important moral dilemmas and conflicting interests, and these can be dealt with through systematic triadic approaches and ethics reflection. 4. A comprehensive implementation program for the selected recommendations is associated with a significantly higher implementation of family involvement for persons with psychotic disorders, compared to no such specific program. 5. Higher implementation of the selected recommendations is associated with improved outcomes for patients and relatives. 6. Outcomes for relatives, patients and the public health- and welfare services justify the costs of implementing family involvement for persons with psychotic disorders.

Interventions

The IFIP intervention consists of the following elements: I. Clinical interventions 1.1 A basic level of family involvement and support 1.2 Family psychoeducation in single-family groups II. Implementation interventions 2.1 Training and guidance of health care personnel 2.2 A family coordinator 2.3 Other implementation measures

Sponsors

Oslo Metropolitan University
CollaboratorOTHER
University Hospital, Akershus
CollaboratorOTHER
Helse Fonna
CollaboratorOTHER
Diakonhjemmet Hospital
CollaboratorOTHER
Vestre Viken Hospital Trust
CollaboratorOTHER
Oslo University Hospital
CollaboratorOTHER
Sykehuset i Vestfold HF
CollaboratorOTHER
Sykehuset Telemark
CollaboratorOTHER_GOV
The Research Council of Norway
CollaboratorOTHER
Helse Sor-Ost
CollaboratorOTHER_GOV
University of Oslo
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Masking description

Patients and relatives will not be informed about their outpatient clinic's allocation status. However, they may deduce this from the kind of treatment they receive. It's impossible to blind the care providers and for practical reasons we won't be able to blind the investigators or the outcomes assessors.

Intervention model description

The study is a cluster randomised controlled trial. Fourteen clusters will be stratified into three strata according to their estimated number of patients with psychotic disorders currently in treatment. The clusters within each stratum will then be randomised to either intervention or control arms with an allocation ratio of 1:1.The seven outpatient units in the intervention arm receives a comprehensive implementation support program, whereas the outpatient clinics in the control arm receives no implementation support. A similar number of patients and relatives will be recruited from both arms, preferably in dyadic pairs, for the quantitative patient- and relative sub study. Employees from the clusters in the intervention arm will be recruited to answer a questionnaire, as part of the implementation study. Patients, relatives and employees will be recruited from the clusters in the intervention arm to take part in qualitative interviews.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Eligibility criteria apply to participants in both quantitative and qualitative sub-studies, except that participation in family psychoeducation as described below is NOT an exclusion criterion in the qualitative sub-study. Inclusion criteria for patients: * To have an established psychotic disorder (F20-29 in ICD-10) or a tentative diagnosis of psychotic disorder, certain enough to begin treatment. This need not be the patient's primary diagnosis. * To be 18 years or older at the time of inclusion.

Exclusion criteria

for patients: * To be sentenced to psychiatric treatment. * Not being competent to consent to participation in research. * Having completed more than five joint sessions of family psychoeducation in single-family groups (patient and relative together) or more than ten joint sessions (multiple families together) in multiple-family groups, or a similarly structured family intervention. * Not having any relatives or next of kin. Inclusion criteria for relatives: * Being a relative of a patient with a diagnosis as described above. * To be 18 years or older at the time of inclusion.

Design outcomes

Primary

MeasureTime frameDescription
Implementation study: Fidelity to the intervention model - Family psychoeducation 1Baseline, 6, 12 and 18 months in the intervention arm. Baseline and 18 months in the control arm.Change in score on fidelity scale for performance and content of family psychoeducation. Rated from 1 (low) to 5 (high).
Implementation study: Fidelity to the intervention model - Family involvement and support 3Baseline, 6, 12 and 18 months in the intervention arm. Baseline and 18 months in the control arm.Change in content, structure and implementation, measured by the scale for family involvement and support. Rated from 1 (low) to 5 (high).
Implementation study: Fidelity to the intervention model - Family involvement and support 2Baseline, 6, 12 and 18 months in the intervention arm. Baseline and 18 months in the control arm.Change in penetration rate, measured by the fidelity scale for family involvement and support. Rated from 1 (low) to 5 (high).
Implementation study: Fidelity to the intervention model - Family involvement and support 1Baseline, 6, 12 and 18 months in the intervention arm. Baseline and 18 months in the control arm.Change in total fidelity measured by the fidelity scale for family involvement and support. Rated from 1 (low) to 5 (high).
Implementation study: Fidelity to the intervention model - Family psychoeducation 2Baseline, 6, 12 and 18 months in the intervention arm. Baseline and 18 months in the control arm.Change in score on fidelity scale for penetration rate and general organisation of family psychoeducation. Rated from 1 (low) to 5 (high).

Secondary

MeasureTime frameDescription
Patient quantitative sub-study: Perceived warmth and criticism from relative.0, 6 and 12 months.Hooley 1989 - 5 items rated 1-10. Completed by patients.
Patient quantitative sub-study: Experienced shared decision making.0, 6 and 12 months.The CollaboRATE questionnaire (3 items rated 0-9), plus two additional items. Completed by patients.
Patient quantitative sub-study: Adherence with medication0, 6 and 12 months for patients and relatives. 0 and 12 months for clinicians.A single question answered by patient, relative and clinician.
Patient quantitative sub-Study: Clinician assessment of patient mental health and functioning0 and 12 months.Health of the Nation Outcome Scale - (HoNOS) scale rated by clinicians on 12 items rated 0-4 (no problem - very serious problem).
Patient quantitative sub-study: Clinician assessment of patient global functioning0 and 12 months.Global Assessment of Functioning Scale - (GAF), split version for symptoms and functioning
Patient quantitative sub-study and economic sub-study: Change in number of hospital admissions.Measured from 18 months before inclusion to 18 months after inclusion.Retrieved from the Norwegian patient registry.
Patient quantitative sub-study: Patient experiences of their own mental health and functioning.0, 6 and 12 months.The Behavior and Symptom Identification scale - (BASIS-24) with 24 questions on mental health, functioning and substance use, on a scale 1-5. Completed by patients.
Patient quantitative sub-study and economic sub-study: Quality of life0, 6 and 12 months.The Recovering Quality of Life - (ReQoL-10) questionnaire with 10 mental health items, and one physical health item on a scale 1-5. Completed by patients.
Patient quantitative sub-study: General satisfaction.0, 6 and 12 months.The Manchester Short Assesment of Quality of Life - (MANSA) questionnaire - first question only, on a scale 1-7. Completed by patients.
Patient quantitative sub-study: Experienced burden of mental health problems.0, 6 and 12 months.A single question - Produced for this study on a scale 1-7. Completed by patients.
Relative quantitative sub-study: Expressed emotion0, 6 and 12 months.The Family questionnaire - (FQ) - 20 items on a four-point scale, measuring criticism and emotional over-involvement. Completed by relatives.
Relative quantitative sub-study: Experienced involvement and shared decision making0, 6 and 12 months.An adapted version of the CollaboRATE questionnaire (3 items rated 0-9), plus two additional items completed by relatives.
Relative quantitative sub-study: Experienced support0, 6 and 12 months.Carer Well-being and Support questionnaire (CWS) v2 short part B - 18 items rated on a four-point scale. Completed by relatives.
Patients' and relatives' quantitative sub-studies and economic sub-study: Use of public health services and resources.Measured from 18 months before inclusion to 18 months after inclusion.Patients' and relatives' use of public health services and resources: Number of appointments with health services, investigations, treatments and medical prescriptions, translated into costs. Retrieved from national registries.
Patients' and relatives' quantitative sub-studies and economic sub-study: Work participationMeasured from 18 months before inclusion to 18 months after inclusion.Patients' and relatives' work participation measured in percentage of a regular full time position. Retrieved from national registries.
Economic sub-study: Increased costs related to implementing and practicing family involvementMeasured before baseline and then throughout the implementation period (0-18 months).Increased costs related to implementing and practicing family involvement in the clinical units in the intervention arm. Compared to normal costs before baseline.
Patient quantitative sub-study and economic sub-study: Change in number of days spent admitted to hospital.Measured from 18 months before inclusion to 18 months after inclusion.Retrieved from the Norwegian patient registry.
Relative quantitative sub-study and economic sub-study: Caregiver quality of life 10, 6 and 12 months.The Care Related Quality of Life - (CarerQoL) questionnaire - Seven questions on a three-point scale. Completed by relatives.
Relative quantitative sub-study and economic sub-study: Caregiver quality of life 20, 6 and 12 months.The Care Related Quality of Life - (CarerQoL) questionnaire - One visual analogue scale (VAS)-question on an 11-point scale, which is also part of the same measure. Completed by relatives.
Relative quantitative sub-study: Experience of caregiving0, 6 and 12 months.The Experience of Caregiving inventory - (ECI) questionnaire - 66 items on a five-point scale covering various aspects of being a caregiver. Completed by relatives.

Other

MeasureTime frameDescription
Patient quantitative sub-study: Drug abuse0 months - baseline screening onlyThe Drug Use Disorders Identification Test - (DUDIT) - 11 items on a three to five-point scale. Completed by patients.
Implementation study: Clinician readiness for change0, 6 and 12 months, approximately.Implementation Process Assessment Tool - (IPAT) a questionnaire (27 items rated 1-6) regarding experience of implementation of a specified practice. Completed by clinicians
Relative quantitative sub-study and implementation study: Exposure to family involvement.Baseline screening, then 6 and 12 monthsUse of different services to involve and support relatives: Family therapy, group support meetings, meetings with the patients' health care personnel, therapy, education on mental health and illness.
Patient quantitative sub-study: Alcohol abuse0 months - baseline screening onlyThe Alcohol Use Disorders Identification Test - (AUDIT) - 10 items on a five-point scale. Completed by patients.
Relative quantitative sub-study and implementation study: Exposure to psychoeducation.Baseline screening, then 6 and 12 monthsParticipation in family psychoeducation measured in number and type of sessions. Reported by relative.
Patient quantitative sub-study and implementation study: Exposure to family psychoeducation.Baseline screening, then 6 and 12 monthsParticipation in family psychoeducation measured in number and type of sessions. Reported by both patient and clinician.

Countries

Norway

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 17, 2026